Free Trial
NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

$18.80
-0.14 (-0.74%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
$18.41
$19.35
50-Day Range
$17.00
$22.81
52-Week Range
$3.60
$28.15
Volume
167,000 shs
Average Volume
1.06 million shs
Market Capitalization
$730.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.67

Longboard Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.3% Upside
$43.67 Price Target
Short Interest
Healthy
13.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.85) to ($2.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

Medical Sector

559th out of 922 stocks

Pharmaceutical Preparations Industry

246th out of 421 stocks

LBPH stock logo

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

LBPH Stock Price History

LBPH Stock News Headlines

Longboard Pharmaceuticals Inc LBPH
LBPH Apr 2024 17.500 put
Recap: Longboard Pharmaceuticals Q4 Earnings
LBPH May 2024 30.000 call
LBPH Mar 2024 22.500 call
LBPH Aug 2024 15.000 put
Longboard Pharmaceuticals, Inc. (LBPH)
See More Headlines
Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
5/26/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LBPH
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.67
High Stock Price Target
$60.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+132.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-54,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.07 per share

Miscellaneous

Free Float
37,076,000
Market Cap
$730.94 million
Optionable
Optionable
Beta
1.25
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Kevin R. Lind (Age 48)
    President, CEO, Secretary & Director
    Comp: $1.07M
  • Ms. Brandi L. Roberts CPA (Age 50)
    M.B.A., Executive VP & CFO
    Comp: $662.65k
  • Dr. Randall E. Kaye M.D. (Age 62)
    Executive VP & Chief Medical Officer
    Comp: $717.95k
  • Mr. Chadwick J. Orevillo MPH
    Executive VP & Head of Operations
  • Megan E. Knight
    VP & Head of Investor Relations
  • Mr. Steven W. Spector J.D. (Age 59)
    Executive VP, Head of Business Development & General Counsel
  • Dr. Anne M. Danks Ph.D.
    VP & Head of Nonclinical Research & Development
  • Mr. Gus Cardenas
    VP & Head of Quality Assurance
  • Dr. Marco Peters Ph.D.
    VP & Head of Translational Science
  • Dr. Dewey McLin Ph.D.
    VP & Head of Medical Affairs

LBPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Longboard Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LBPH shares.
View LBPH analyst ratings
or view top-rated stocks.

What is Longboard Pharmaceuticals' stock price target for 2024?

6 brokerages have issued twelve-month target prices for Longboard Pharmaceuticals' shares. Their LBPH share price targets range from $32.00 to $60.00. On average, they expect the company's share price to reach $43.67 in the next year. This suggests a possible upside of 132.3% from the stock's current price.
View analysts price targets for LBPH
or view top-rated stocks among Wall Street analysts.

How have LBPH shares performed in 2024?

Longboard Pharmaceuticals' stock was trading at $6.03 on January 1st, 2024. Since then, LBPH shares have increased by 211.8% and is now trading at $18.80.
View the best growth stocks for 2024 here
.

When is Longboard Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our LBPH earnings forecast
.

How were Longboard Pharmaceuticals' earnings last quarter?

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) released its earnings results on Thursday, May, 2nd. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.06.

What ETFs hold Longboard Pharmaceuticals' stock?

ETFs with the largest weight of Longboard Pharmaceuticals (NASDAQ:LBPH) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

When did Longboard Pharmaceuticals IPO?

Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

Who are Longboard Pharmaceuticals' major shareholders?

Longboard Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.46%), Farallon Capital Management LLC (7.56%), Price T Rowe Associates Inc. MD (5.70%), Vanguard Group Inc. (4.79%), Jennison Associates LLC (2.62%) and Lord Abbett & CO. LLC (1.32%).
View institutional ownership trends
.

How do I buy shares of Longboard Pharmaceuticals?

Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LBPH) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners